Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 2/2017

Open Access 01-12-2017 | Review

Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review

Author: Jan M. Keppel Hesselink

Published in: Pain and Therapy | Issue 2/2017

Login to get access

Abstract

The identification of a number of families of lipid signal molecules since the 1990s created new therapeutic possibilities for a great number of disorders characterized by chronic inflammation and pain. These lipid autacoids have been explored in a great variety of animal models related to inflammation, pain, (neuro-)protection, and repair. Based on the data from these models, as well as on a number of proof of principle studies in the clinic in indications such as neuropathic pain, a new chapter in medicine is about to begin. We would like to introduce the term “Autacoid Pain Medicine” for this chapter. There are, however, a number of methodological and strategic issues to overcome in this field. One of the roadblocks is related to patent strategies around families of these molecules. As this is not always recognized we will present a number of examples.
Literature
1.
Keppel Hesselink JM. The terms ‘autacoid’, ‘hormone’ and ‘chalone’ and how they have shifted with time. Auton Autacoid Pharmacol. 2015;35:51–8.CrossRefPubMed
2.
Silva M. The physiological significance of bradykinin. Ann N Y Acad Sci. 1963;104(1):190–211.CrossRef
3.
4.
Lewis Wright R, Ames Adelbert III. Measurement of maximal permissible cerebral ischemia and a study of its pharmacologic prolongation*. J Neurosurg. 1964;21(7):567–74.CrossRef
5.
Melmon KL, Rocklin RE, Rosenkranz RP. Autacoids as modulators of the inflammatory and immune response. Am J Med. 1981;71(1):100–6.CrossRefPubMed
6.
Costa E. To follow where nature leads. Washington: Lectio Magistralis; 1986.
7.
8.
Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514–20.CrossRefPubMed
9.
Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med. 2002;196:1025–37.CrossRefPubMedPubMedCentral
10.
Della Valle F. FIDIA-Georgetown Institute for the Neurosciences: dreams, projects and actions with Erminio Costa. Pharmacol Res. 2011;64(4):310–1.CrossRef
11.
Keppel Hesselink JM. Palmitoylethanolamide: research Synergy between academia and industry, based on insights and work of nobel laureate rita levi-montalcini. J Clin Trials Pat. 2016;1(1):3.
12.
Della Valle F., Silvana Lorenzi, Jacobus C. J. J. Samson, and Federica della Valle. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes. Patent US 5506224 A, priority date 31 December 1991.
13.
Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam. 2013;2013:151028.CrossRefPubMedPubMedCentral
14.
Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA. 1984;81(17):5335–9.CrossRefPubMedPubMedCentral
15.
Samuelsson B, Serhan C, and Hamberg M. Inflammatory lipoxin A and anti-inflammatory lipoxin B compounds US 4560514 A, priority date 4 May 1984.
16.
Serhan CN, and Badr K. Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis, WO1990013292A1, priority date 27 April 1989.
17.
Serhan CN. Lipoxin compounds, WO 1994029262 A1, priority date 15 June 1994).
18.
Serhan CN. Lipoxin compounds and their use in treating cell proliferative disorders, WO1998011049A1, priority date 15 June 1994.
19.
Serhan CN. Inhibition of TNF-alpha-initiated neutrophil response, US 20040192785 A1, priority date 18 March 1999.
20.
Serhan CN. Aspirin-triggered lipid mediators, WO2001060778A2, priority date 16 February 2000.
21.
Van Dyke TE, Petasis NA, and Serhan CN. Lipoxin analogs and methods for the treatment of periodontal disease, WO2001070664A2, priority date 20 March 2000.
22.
Serhan CN. Lipoxin compounds, US 5441951 A, priority date 15 June 1994.
23.
Hachicha M, Pouliot M, Petasis NA, Serhan CN. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med. 1999;189(12):1923–30.CrossRefPubMedPubMedCentral
24.
Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol. 2013;168(1):172–8.CrossRefPubMed
25.
Chandrasekharan JA, Sharma-Walia N. Lipoxins: nature’s way to resolve inflammation. J Inflamm Res. 2015;30(8):181–92.
26.
Zhu M, Wang X, Hjorth E, Colas RA, Schroeder L, Granholm AC, Serhan CN, Schultzberg M. Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis. Mol Neurobiol. 2016;53(4):2733–49.CrossRefPubMed
27.
Klein CP, Sperotto ND, Maciel IS, Leite CE, Souza AH, Campos MM. Effects of d-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology. 2014;86:57–66.CrossRefPubMed
28.
Dalli J, Colas RA, Quintana C, Barragan-Bradford D, Hurwitz S, Levy BD, Choi AM, Serhan CN, Baron RM. Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes. Crit Care Med. 2016;45(1):58–68.CrossRef
29.
Zambalde ÉP, Teixeira MM, Favarin DC, de Oliveira JR, Magalhães ML, Cunha MM, Silva WC, Okuma CH, Rodrigues V, Levy BD, Rogerio AP. The anti-inflammatory and pro-resolution effects of aspirin-triggered RvD1 (AT-RvD1) on peripheral blood mononuclear cells from patients with severe asthma. Int Immunopharmacol. 2016;35:142–8.CrossRefPubMed
30.
Kang JW, Lee SM. Resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and efferocytosis. Biochim Biophys Acta. 2016;1861(9):1025–35.CrossRefPubMed
31.
32.
Keppel Hesselink JM, Chiosi F, Costagliola C. Resolvins and aliamides: lipid autacoids in ophthalmology—what promise do they hold? Drug Des Devel Ther. 2016;10:3133–41.CrossRef
33.
Titos E, Rius B, López-Vicario C, Alcaraz-Quiles J, García-Alonso V, Lopategi A, Dalli J, Lozano JJ, Arroyo V, Delgado S, Serhan CN, Clària J. Signaling and immunoresolving actions of resolvin D1 in inflamed human visceral adipose tissue. J Immunol. 2016;197(8):3360–70.CrossRefPubMedPubMedCentral
34.
Luo B, Han F, Xu K, Wang J, Liu Z, Shen Z, Li J, Liu Y, Jiang M, Zhang ZY, Zhang Z. Resolvin D1 programs inflammation resolution by increasing TGF-β expression induced by dying cell clearance in experimental autoimmune neuritis. J Neurosci. 2016;36(37):9590–603.CrossRefPubMed
35.
Arnardottir HH, Dalli J, Norling LV, Colas RA, Perretti M, Serhan CN. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation. J Immunol. 2016;197(6):2362–8.CrossRefPubMedPubMedCentral
36.
Benabdoune H, Rondon EP, Shi Q, Fernandes J, Ranger R, Fahmi H, Benderdour M. The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflamm Res. 2016;65(8):635–45.CrossRefPubMed
37.
38.
Liu ZH, Miao GS, Wang JN, Yang CX, Fu ZJ, Sun T. Resolvin D1 Inhibits Mechanical Hypersensitivity in Sciatica by Modulating the Expression of Nuclear Factor-κB, Phospho-extracellular Signal-regulated Kinase, and Pro- and Anti-inflammatory Cytokines in the Spinal Cord and Dorsal Root Ganglion. Anesthesiology. 2016;124(4):934–44.CrossRefPubMed
39.
Xu ZZ, Berta T, Ji RR. Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol. 2013;8(1):37–41.CrossRefPubMed
40.
Fernández-Ruiz J, Romero J, Ramos JA. Endocannabinoids and neurodegenerative disorders: Parkinson’s disease, Huntington’s Chorea, Alzheimer’s disease, and others. Handb Exp Pharmacol. 2015;231:233–59.CrossRefPubMed
41.
42.
Kianian M, Al-Banna NA, Kelly ME, Lehmann C. Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. J Basic Clin Physiol Pharmacol. 2013;24(1):27–33.CrossRefPubMed
43.
Zoerner AA, Stichtenoth DO, Engeli S, Batkai S, Winkler C, Schaumann F, Janke J, Holz O, Krug N, Tsikas D, Jordan J, Hohlfeld JM. Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma. Clin Pharmacol Ther. 2011;90(3):388–91.CrossRefPubMed
44.
Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;153(2):252–62.CrossRefPubMed
45.
Chen J, Matias I, Dinh T, Lu T, Venezia S, Nieves A, Woodward DF, Di Marzo V. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330(4):1062–7.CrossRefPubMed
46.
Kim J, Li Y, Watkins BA. Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat. 2013;104–105:32–41.CrossRefPubMed
47.
Pryce G, Baker D. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Handb Exp Pharmacol. 2015;231:213–31.CrossRefPubMed
48.
Gui H, Tong Q, Qu W, Mao CM, Dai SM. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. Int Immunopharmacol. 2015;26(1):86–91.CrossRefPubMed
49.
La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, García-Gutiérrez MS, De la Torre R, Manzanares J, Monfort J, Maldonado R. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015;156(10):2001–12.CrossRefPubMedPubMedCentral
50.
Patsenker E, Sachse P, Chicca A, Gachet MS, Schneider V, Mattsson J, Lanz C, Worni M, de Gottardi A, Semmo M, Hampe J, Schafmayer C, Brenneisen R, Gertsch J, Stickel F, Semmo N. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci. 2015;16(4):7057–76.CrossRefPubMedPubMedCentral
51.
Kinsey SG, Long JZ, O’Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther. 2009;330(3):902–10.CrossRefPubMedPubMedCentral
52.
Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016;157(Suppl 1):S23–32.CrossRefPubMed
53.
Cipriano M, Esposito G, Negro L, Capoccia E, Sarnelli G, Scuderi C, De Filippis D, Steardo L, Iuvone T. Palmitoylethanolamide regulates production of pro-angiogenic mediators in a model of β amyloid-induced astrogliosis in vitro. CNS Neurol Disord Drug Targets. 2015;14(7):828–37.CrossRefPubMed
54.
Yu HL, Deng XQ, Li YJ, Li YC, Quan ZS, Sun XY. N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. Pharmacol Rep. 2011;63(3):834–9.CrossRefPubMed
55.
Redlich S, Ribes S, Schütze S, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J Neuroinflammation. 2014;14(11):108.CrossRef
56.
Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int Arch Allergy Immunol. 2005;138(1):80–7.CrossRefPubMed
57.
Impellizzeri D, Bruschetta G, Ahmad A, Crupi R, Siracusa R, Di Paola R, Paterniti I, Prosdocimi M, Esposito E, Cuzzocrea S. Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion. Eur J Pharmacol. 2015;5(762):136–49.CrossRef
58.
Keppel Hesselink JM, Costagliola C, Fakhry J, Kopsky DJ. Palmitoylethanolamide, a natural retinoprotectant: its putative relevance for the treatment of glaucoma and diabetic retinopathy. J Ophthalmol. 2015;2015:430596.CrossRefPubMedPubMedCentral
59.
Mattace Raso G, Santoro A, Russo R, Simeoli R, Paciello O, Di Carlo C, Diano S, Calignano A, Meli R. Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats. Endocrinology. 2014;155(4):1291–301.CrossRefPubMedPubMedCentral
60.
Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci. 2008;28(4):633–41.CrossRefPubMed
61.
Bonezzi FT, Sasso O, Pontis S, Realini N, Romeo E, Ponzano S, Nuzzi A, Fiasella A, Bertozzi F, Piomelli D. An important role for N-acylethanolamine acid amidase in the complete Freund’s adjuvant rat model of arthritis. J Pharmacol Exp Ther. 2016;356(3):656–63.CrossRefPubMed
62.
Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26(2):99–104.PubMed
63.
Rasková H, Masek K, Linèt O. Non-specific resistance induced by palmitoylethanolamide. Toxicon. 1972;10(5):485–90.CrossRefPubMed
64.
KeppelHesselink JM, Kopsky DJ. Palmitoylethanolamide, a nutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729–34.CrossRef
65.
Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J. 2013;13(6):49–53.CrossRef
66.
Ji RR, and Serhan CN. A method for treating neuropathic pain, WO 2011034887 A2, priority date September 15, 2009.
67.
Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji R. Resolvins RvE1 and RvD1attenuate inflammatory pain via central and peripheral actions. Nat Med. 2010;16(5):592–7.CrossRefPubMedPubMedCentral
68.
Jo YY, Lee JY, Park CK. Resolvin E1 inhibits substance P-induced potentiation of TRPV1 in primary sensory neurons. Mediators Inflamm. 2016;2016:5259321.CrossRefPubMedPubMedCentral
69.
Xu ZZ, Berta T, Ji RR. Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol. 2013;8(1):37–41.CrossRefPubMed
70.
Xu ZZ, Berta T. Ji R. R. Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol. 2013;8(1):37–41.CrossRefPubMed
71.
Paladini A, Fusco M, Coaccioli S, Skaper SD, Varrassi G. Chronic pain in the elderly: the case for new therapeutic strategies. Pain Physician. 2015;18(5):E863–76.PubMed
72.
Keppel Hesselink JM. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J. 2012;5:12–23.CrossRef
73.
Keppel Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437–42.CrossRef
74.
Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J. 2013;13(6):49–53.CrossRef
75.
Keppel Hesselink JM. Pain management. In: Flint G, Rusbridge C, editors. Syringomyelia, A Disorder of CSF Circulation. Berlin: Springer-Verlag; 2014. p. 237–60.
76.
Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a nutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729–34.CrossRefPubMedPubMedCentral
77.
Keppel Hesselink JM, Costagliola C, Fakhry J, Kopsky DJ. Palmitoylethanolamide, a natural retinoprotectant: its putative relevance for the treatment of glaucoma and diabetic retinopathy. J Ophthalmol. 2015;. doi:10.​1155/​2015/​430596.PubMedPubMedCentral
78.
Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J. 2013;13(6):49–53.CrossRef
Metadata
Title
Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review
Author
Jan M. Keppel Hesselink
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 2/2017
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-017-0075-4

Other articles of this Issue 2/2017

Pain and Therapy 2/2017 Go to the issue

Review

Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set

Original Research

Deaths from Opioid Overdosing: Implications of Coroners’ Inquest Reports 2008–2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study

Review

A Review of Current and Emerging Approaches to Pain Management in the Emergency Department

Original Research

Sublingual Buprenorphine Efficacy in Renal Colic Pain Relief: A Randomized Placebo-Controlled Clinical Trial

Editorial

Why We Still Need To Speak About Sex Differences and Sex Hormones in Pain

Review

Pain as a First Manifestation of Paraneoplastic Neuropathies: A Systematic Review and Meta-Analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits